These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 33819719)

  • 1. Association of thrombotic microangiopathy with atezolizumab therapy in cancer patients.
    Izzedine H; Mathian A; Albiges L; Champiat S; Brocheriou I
    Eur J Cancer; 2021 May; 149():34-36. PubMed ID: 33819719
    [No Abstract]   [Full Text] [Related]  

  • 2. Atezolizumab-induced type 1 diabetes mellitus in a patient with metastatic renal cell carcinoma.
    Rahman W; Conley A; Silver KD
    BMJ Case Rep; 2020 Jul; 13(7):. PubMed ID: 32616532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Axitinib Reverses Resistance to Anti-Programmed Cell Death-1 Therapy in a Patient With Renal Cell Carcinoma.
    Yang Y; Huang H; Li T; Gao Q; Song Y; Wang Z
    Front Immunol; 2021; 12():728750. PubMed ID: 34764951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors.
    Hwang I; Park I; Yoon SK; Lee JL
    Clin Genitourin Cancer; 2020 Apr; 18(2):e122-e133. PubMed ID: 31837940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis.
    Mori K; Pradere B; Quhal F; Katayama S; Mostafaei H; Laukhtina E; Schuettfort VM; D'Andrea D; Egawa S; Bensalah K; Schmidinger M; Powles T; Shariat SF
    Cancer Treat Rev; 2021 Sep; 99():102242. PubMed ID: 34153830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.
    Rini BI; Powles T; Atkins MB; Escudier B; McDermott DF; Suarez C; Bracarda S; Stadler WM; Donskov F; Lee JL; Hawkins R; Ravaud A; Alekseev B; Staehler M; Uemura M; De Giorgi U; Mellado B; Porta C; Melichar B; Gurney H; Bedke J; Choueiri TK; Parnis F; Khaznadar T; Thobhani A; Li S; Piault-Louis E; Frantz G; Huseni M; Schiff C; Green MC; Motzer RJ;
    Lancet; 2019 Jun; 393(10189):2404-2415. PubMed ID: 31079938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell Carcinoma.
    Varkaris A; Xu W; Davis RB; Healy B; McDermott DF
    Clin Genitourin Cancer; 2020 Jun; 18(3):179-184.e3. PubMed ID: 32144046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T cell mediated hypersensitivity to previously tolerated iodinated contrast media precipitated by introduction of atezolizumab.
    Hammond S; Olsson-Brown A; Gardner J; Thomson P; Ali SE; Jolly C; Carr D; Ressel L; Pirmohamed M; Naisbitt D
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitor associated renally limited thrombotic microangiopathy - a clinical dilemma.
    Badra S; Ruchi R; Zeng X; Gordan L; Shah CV
    Eur J Cancer; 2022 Jul; 169():126-130. PubMed ID: 35561455
    [No Abstract]   [Full Text] [Related]  

  • 10. Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study.
    McDermott DF; Sosman JA; Sznol M; Massard C; Gordon MS; Hamid O; Powderly JD; Infante JR; Fassò M; Wang YV; Zou W; Hegde PS; Fine GD; Powles T
    J Clin Oncol; 2016 Mar; 34(8):833-42. PubMed ID: 26755520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombotic microangiopathy caused by oral contraceptives in a kidney transplant recipient.
    Shirai H; Yashima J; Tojimbara T; Honda K
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():41-3. PubMed ID: 26970708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Avelumab and axitinib combination therapy for the treatment of advanced renal cell carcinoma.
    Soleimani M; Nappi L; Kollmannsberger C
    Future Oncol; 2020 Dec; 16(36):3021-3034. PubMed ID: 32856478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cabozantinib-induced renal thrombotic microangiopathy.
    La Manna G; Baraldi O; Corradetti V; Comai G
    Nephrology (Carlton); 2018 Jan; 23(1):96-97. PubMed ID: 29250919
    [No Abstract]   [Full Text] [Related]  

  • 14. Renal thrombotic microangiopathy caused by bevacizumab.
    Horino T; Ichii O; Shimamura Y; Terada Y
    Nephrology (Carlton); 2018 Apr; 23(4):378-379. PubMed ID: 29520904
    [No Abstract]   [Full Text] [Related]  

  • 15. Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma.
    Pal SK; McDermott DF; Atkins MB; Escudier B; Rini BI; Motzer RJ; Fong L; Joseph RW; Oudard S; Ravaud A; Bracarda S; Suárez C; Lam ET; Choueiri TK; Ding B; Quach C; Hashimoto K; Schiff C; Piault-Louis E; Powles T
    BJU Int; 2020 Jul; 126(1):73-82. PubMed ID: 32233107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
    Atkins MB; Clark JI; Quinn DI
    Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy.
    Costero O; Picazo ML; Zamora P; Romero S; Martinez-Ara J; Selgas R
    Nephrol Dial Transplant; 2010 Mar; 25(3):1001-3. PubMed ID: 20019017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunotherapy of renal cell cancer].
    Géczi L; Nagyiványi K; Maráz A
    Magy Onkol; 2017 Jun; 61(2):126-131. PubMed ID: 28585613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.
    McGregor BA; Lalani AA; Xie W; Steinharter JA; E Bakouny Z; Martini DJ; Fleischer JH; Abou-Alaiwi S; Nassar A; Nuzzo PV; Kaymakcalan MD; Braun DA; Wei XX; Harshman LC; Bilen MA; Choueiri TK
    Eur J Cancer; 2020 Aug; 135():203-210. PubMed ID: 32599410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring of the Evolution of Immune Checkpoint Inhibitor Myocarditis With Cardiovascular Magnetic Resonance.
    Sato T; Nakamori S; Watanabe S; Nishikawa K; Inoue T; Imanaka-Yoshida K; Ishida M; Sakuma H; Ito M; Dohi K
    Circ Cardiovasc Imaging; 2020 Nov; 13(11):e010633. PubMed ID: 33153280
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.